Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge

Grimshaw MJ, Papazisis K, Picco G, Bohnenkamp H, Noll T, Taylor-Papadimitriou J, Burchell J (2008)
British Journal of Cancer 98(4): 784-791.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Abstract
Dendritic cells (DCs) 'pulsed' with an appropriate antigen may elicit an antitumour immune response in mouse models. However, while attempting to develop a DC immunotherapy protocol for the treatment of breast cancer based on the tumour-associated MUC1 glycoforms, we found that unpulsed DCs can affect tumour growth. Protection from RMA-MUC1 tumour challenge was achieved in C57Bl/6 MUC1 transgenic mice by immunising with syngeneic DCs pulsed with a MUC1 peptide. However, unpulsed DCs gave a similar level of protection, making it impossible to evaluate the effect of immunisation of mice with DCs pulsed with the specific peptide. Balb/C mice could also be protected from tumour challenge by immunisation with unpulsed DCs prior to challenge with murine mammary tumour cells (410.4) or these cells transfected with MUC1 (E3). Protection was achieved with as few as three injections of 50 000 naive DCs per mouse per week, was not dependent on injection route, and was not specific to cell lines expressing human MUC1. However, the use of Rag2-knockout mice demonstrated that the adaptive immune response was required for tumour rejection. Injection of unpulsed DCs into mice bearing the E3 tumour slowed tumour growth. In vitro, production of IFN-gamma and IL-4 was increased in splenic cells isolated from mice immunised with DCs. Depleting CD4 T cells in vitro partially decreased cytokine production by splenocytes, but CD8 depletion had no effect. This paper shows that naive syngeneic DCs may induce an antitumour immune response and has implications for DC immunotherapy preclinical and clinical trials.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Grimshaw MJ, Papazisis K, Picco G, et al. Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge. British Journal of Cancer. 2008;98(4):784-791.
Grimshaw, M. J., Papazisis, K., Picco, G., Bohnenkamp, H., Noll, T., Taylor-Papadimitriou, J., & Burchell, J. (2008). Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge. British Journal of Cancer, 98(4), 784-791.
Grimshaw, M. J., Papazisis, K., Picco, G., Bohnenkamp, H., Noll, T., Taylor-Papadimitriou, J., and Burchell, J. (2008). Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge. British Journal of Cancer 98, 784-791.
Grimshaw, M.J., et al., 2008. Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge. British Journal of Cancer, 98(4), p 784-791.
M.J. Grimshaw, et al., “Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge”, British Journal of Cancer, vol. 98, 2008, pp. 784-791.
Grimshaw, M.J., Papazisis, K., Picco, G., Bohnenkamp, H., Noll, T., Taylor-Papadimitriou, J., Burchell, J.: Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge. British Journal of Cancer. 98, 784-791 (2008).
Grimshaw, M. J., Papazisis, K., Picco, G., Bohnenkamp, H., Noll, Thomas, Taylor-Papadimitriou, J., and Burchell, J. “Immunisation with 'naive' syngeneic dendritic cells protects mice from tumour challenge”. British Journal of Cancer 98.4 (2008): 784-791.
This data publication is cited in the following publications:
This publication cites the following data publications:

1 Citation in Europe PMC

Data provided by Europe PubMed Central.

MUC1 immunotherapy.
Beatson RE, Taylor-Papadimitriou J, Burchell JM., Immunotherapy 2(3), 2010
PMID: 20635898

40 References

Data provided by Europe PubMed Central.

Type I interferons produced by dendritic cells promote their phenotypic and functional activation.
Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF., Blood 99(9), 2002
PMID: 11964292
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E., Nat. Med. 6(9), 2000
PMID: 10973321
Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.
Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J., Cancer Res. 52(7), 1992
PMID: 1372533
Dendritic cells in a mature age.
Reis e Sousa C., Nat. Rev. Immunol. 6(6), 2006
PMID: 16691244
Purification of splenic dendritic cells induces maturation and capacity to stimulate Th1 response in vivo.
Schlecht G, Mouries J, Poitrasson-Riviere M, Leclerc C, Dadaglio G., Int. Immunol. 18(3), 2006
PMID: 16415098
The use of dendritic cells in cancer immunotherapy.
Schuler G, Schuler-Thurner B, Steinman RM., Curr. Opin. Immunol. 15(2), 2003
PMID: 12633662
Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G., J. Immunol. 172(2), 2004
PMID: 14707109
Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA., J. Immunol. 171(11), 2003
PMID: 14634094
Dendritic cell-based cancer immunotherapy targeting MUC-1.
Wierecky J, Mueller M, Brossart P., Cancer Immunol. Immunother. 55(1), 2006
PMID: 15864588
Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S, Darrow TL, Vervaert CE, Seigler HF., Cell. Immunol. 179(1), 1997
PMID: 9259775
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ., J. Exp. Med. 183(1), 1996
PMID: 8551248

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 18253127
PubMed | Europe PMC

Search this title in

Google Scholar